CoChat

Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism

Hutten, BA, Prins, MH · 2000 · Cochrane Database of Systematic Reviews
Cited by 43

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Currently the most frequently used secondary treatment for patients with venous thromboembolism are vitamin K antagonists targeted at an INR of 2.5 (range 2.0 - 3.0). However, based on the continuing risk of bleeding and uncertainty regarding the risk of recurrent venous thromboembolism, there is discussion on the proper duration of treatment with vitamin K antagonists for these patients. Recently, several studies were published in which the risk and benefits of different durations of oral anticoagulants were compared in patients with venous thromboembolism. OBJECTIVES: The objective of this review was to evaluate efficacy and safety of different durations of treatment with vitamin K antagonists in patients with symptomatic venous thromboembolism. SEARCH STRATEGY: The reviewers sought publications through computerized searches of MEDLINE and EMBASE, and by hand-searching relevant journals, using the search strategy described by the Cochrane Review Group on Peripheral Vascular Diseases. They also contacted colleagues. SELECTION CRITERIA: Randomized controlled clinical trials comparing different durations of treatment with vitamin K antagonists in patients with symptomatic venous thromboembolism. DATA COLLECTION AND ANALYSIS: Two reviewers extracted the data and assessed the quality of the trials independently. MAIN RESULTS: Four studies with a total of exactly 1500 patients were included. A consistent reduction for the risk of recurrent events was observed during prolonged treatment with vitamin K antagonists (OR 0.15; 95% CI [0.10 - 0.23]) independent of the period elapsed since the index thrombotic event. A 'rebound' phenomenon, i.e. an excess of recurrences shortly after cessation of the prolonged treatment was not observed (OR 1.11; 95% CI [0.71 - 1.75]). In addition, a substantial increase in bleeding complications was found during the entire period after randomization (OR 7.75; 95% CI [1.08 - 55.57]). REVIEWER'S CONCLUSIONS: In conclusion this meta-analysis shows that treatment with vitamin K antagonists reduces the risk of recurrent venous thromboembolism as long as it is used. However, the absolute risk of recurrent venous thromboembolism declines over time, while the risk for major bleeding remains. Thus, the efficiency of vitamin K antagonist administration decreases over time since the index event.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd001367

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 21

  1. Kearon, 1999, A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism, New England Journal of Medicine, 340, 901, 10.1056/NEJM199903253401201 · DOI · Paper page
  2. Pinede, 2001, Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis, Circulation, 103, 2453, 10.1161/01.CIR.103.20.2453 · DOI · Paper page
  3. Schulman, 1995, A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism, New England Journal of Medicine, 332, 1661, 10.1056/NEJM199506223322501 · DOI · Paper page
  4. Schulman, 1997, The duration of oral anticoagulant therapy after a second episode of venous thromboembolism, New England Journal of Medicine, 336, 393, 10.1056/NEJM199702063360601 · DOI · Paper page
  5. Andersson, 1984, Antithrombin III in patients with acute deep vein thrombosis during heparin treatment (subcutaneous and intravenous) and during and after treatment with oral coumarins, Thrombosis Research, 34, 333, 10.1016/0049-3848(84)90390-6 · DOI
  6. Fennerty, 1987, A comparison of 3 and 6 weeks' anticoagulation in the treatment of venous thromboembolism, Clinical & Laboratory Haematology, 9, 17, 10.1111/j.1365-2257.1987.tb01377.x · DOI · Paper page
  7. Holmgren, 1985, One-month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis, Acta Medica Scandinavica, 218, 279, 10.1111/j.0954-6820.1985.tb06125.x · DOI
  8. Lagerstedt, 1985, Need for long term anticoagulant treatment in symptomatic calf vein thrombosis, Lancet, 2, 515, 10.1016/S0140-6736(85)90459-3 · DOI · Paper page
  9. O'Sullivan, 1972, Duration of anticoagulant therapy in venous thrombo-embolism, Medical Journal of Australia, 2, 1104, 10.5694/j.1326-5377.1972.tb103752.x · DOI
  10. Schulman, 1985, The duration of oral anticoagulation after deep vein thrombosis. A randomized study, Acta Medica Scandinavica, 217, 547, 10.1111/j.0954-6820.1985.tb03261.x · DOI
  11. Sudlow, 1992, Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism, Lancet, 340, 873, 10.1016/0140-6736(92)93285-U · DOI · Paper page
  12. Collins, 1987, Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews, Statistics in Medicine, 6, 245, 10.1002/sim.4780060308 · DOI · Paper page
  13. Hull, 1979, Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis, New England Journal of Medicine, 301, 855, 10.1056/NEJM197910183011602 · DOI · Paper page
  14. Koopman, 1996, The Tasman Study Group. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home, New England Journal of Medicine, 334, 682, 10.1056/NEJM199603143341102 · DOI · Paper page
  15. Lagerstedt, 1985, Need for long term anticoagulant treatment in symptomatic calf vein thrombosis, Lancet, 2, 515, 10.1016/S0140-6736(85)90459-3 · DOI · Paper page
  16. Levine, 1996, A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis, New England Journal of Medicine, 334, 677, 10.1056/NEJM199603143341101 · DOI · Paper page
  17. Mantel, 1959, Statistical aspects of the analysis of data from retrospective studies of disease, Journal of the National Cancer Institute, 22, 719
  18. Prandoni, 1996, The long-term clinical course of acute deep venous thrombosis, Annals of Internal Medicine, 125, 1, 10.7326/0003-4819-125-1-199607010-00001 · DOI · Paper page
  19. Prins, 1999, The optimal duration of secondary prevention with oral anticoagulants in patients with venous thromboembolism. A decision analysis, Thromb & Haemost, Suppl, 7
  20. Prins, 1999, Duration of oral anticoagulant treatment in patients with venous thromboembolism and a deficiency of antithrombin, protein C or protein S: a decision analysis, Thromb & Haemost, Suppl, 180
  21. Yusuf, 1985, Beta blockade during and after myocardial infarction: an overview of the randomized trials, Progress in Cardiovascular Diseases, 27, 335, 10.1016/S0033-0620(85)80003-7 · DOI · Paper page

Cited by

See all 43

Metadata

Authors
Hutten, B., & Prins, M.
Venue
Cochrane Database of Systematic Reviews
Published
2000-04-24
Issue
2
Pages
CD001333-CD001333
ISSN
1361-6137 (ISSN-L)
OpenAlex
W4249177926
Cited by
43
References
2
Type
reference entry
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.